{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["TODAY Study Group"],"funding":["NCATS NIH HHS","NCRR NIH HHS","NIDDK NIH HHS"],"pagination":["1742-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3661839"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(6)"],"pubmed_abstract":["<h4>Objective</h4>The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control. We report here treatment effects on measures of body composition and their relationships to demographic and metabolic variables including glycemia.<h4>Research design and methods</h4>Measures of adiposity (BMI, waist circumference, abdominal height, percent and absolute fat, and bone mineral content [BMC] and density [BMD]) were analyzed as change from baseline at 6 and 24 months.<h4>Results</h4>Measures of fat accumulation were greatest in subjects treated with M+R and least in M+L. Although fat measures in M+L were less than tho"],"journal":["Diabetes care"],"pubmed_title":["Treatment effects on measures of body composition in the TODAY clinical trial."],"pmcid":["PMC3661839"],"funding_grant_id":["UL1 TR000130","M01 RR001066","U01 DK061242","UL1-RR-024153","UL1-RR-025780","UL1-RR-024134","UL1-RR-024992","M01-RR-00125","UL1 TR000439","UL1-RR-024139","M01-RR-00069","UL1-RR-024989","UL1-RR-025758","U01-DK-61230","UL1 RR024139","U01-DK-61254","UL1 RR024134","UL1 RR024992","U01-DK-61212","M01 RR000036","UL1 RR025780","UL1 RR024153","U01-DK-61239","U01 DK061230","M01 RR000084","U01 DK061254","M01-RR-01066","M01 RR014467","UL1 TR000005","U01 DK061239","U01 DK061212","UL1 TR000448","M01-RR-00036","UL1 RR024989","UL1 RR025758","M01-RR-00084","U01-DK-61242","M01 RR000125","M01 RR000069","M01 RR000043","M01-RR-00043-45"],"pubmed_authors":["Shepherd J","Copeland KC","Pyle L","Grey M","Lipman TH","Washington G","Hirst K","El ghormli L","TODAY Study Group","Kriska AM","Delahanty L","Higgins J"],"additional_accession":[]},"is_claimable":false,"name":"Treatment effects on measures of body composition in the TODAY clinical trial.","description":"<h4>Objective</h4>The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial showed superiority of metformin plus rosiglitazone (M+R) over metformin alone (M), with metformin plus lifestyle (M+L) intermediate in maintaining glycemic control. We report here treatment effects on measures of body composition and their relationships to demographic and metabolic variables including glycemia.<h4>Research design and methods</h4>Measures of adiposity (BMI, waist circumference, abdominal height, percent and absolute fat, and bone mineral content [BMC] and density [BMD]) were analyzed as change from baseline at 6 and 24 months.<h4>Results</h4>Measures of fat accumulation were greatest in subjects treated with M+R and least in M+L. Although fat measures in M+L were less than tho","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Jun","modification":"2025-04-22T07:11:01.957Z","creation":"2019-03-27T01:10:18Z"},"accession":"S-EPMC3661839","cross_references":{"pubmed":["23704673"],"doi":["10.2337/dc12-2534"]}}